The Jackson Laboratory has developed a new platform to provide a fast, accurate and reliable method for screening novel immunotherapy treatments for efficacy and cytokine release syndrome.

While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly, the clinical benefit seen with these ...

Panelists discuss how real-world data on the incidence of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) compare with clinical trial findings as ...

This is also known as cytokine release syndrome (CRS) or a "cytokine storm." A cytokine storm is a severe immune response that causes symptoms like a high fever, headache, nausea, and severe fatigue.

TCEs’ shortcomings include on-target, off-tumor toxicity, short half-life, low tumor uptake and retention, and immune over-stimulation, which leads to cytokine-release syndrome (CRS) and T-cell ...

Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

So, this is a CD19 T-cell engager designed to bind with low affinity to CD3 T cells to potentially lower the risk of CRS [cytokine release syndrome], and then it targets CD19 on B cells similar to ...

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical ...